Anelixis announces the conclusion of AT-1501 Phase 1 clinical trial
Category: #health  By Saipriya Iyer  Date: 2019-11-23
  • share
  • Twitter
  • Facebook
  • LinkedIn

Anelixis announces the conclusion of AT-1501 Phase 1 clinical trial

Anelixis Therapeutics has reportedly concluded its testing of an investigational antibody, AT-1501, in a Phase 1 clinical trial in healthy volunteers as well as eight patients suffering from amyotrophic lateral sclerosis (ALS). The company further announced that it has raised enough funds to advance to AT-1501’s Phase 2 clinical trial.

The Phase 1 trial came out with a positive result as AT-1501 was well-tolerated at every dose that was tested. The processing of the drug inside the body, which is also called pharmacokinetics, was the same as was predicted by the researchers. The details of the study are to be presented at scientific meetings expected held in the future.

The company anticipates this data to support more clinical studies regarding ALS as well as other disorders to further analyze the tolerability and safety of AT-1501, including other clinical parameters like potential biomarkers.

AT-1501 happens to be an investigational antibody targeting CD40 ligand (CD40L), which is essentially a kind of protein on the surface of white blood cells causing inflammation. The U.S. Food and Drug Administration has given this therapy the designation of an orphan drug. 

The ALS Therapy Development Institute (ALS TDI) has developed AT-1501 with the help of numerous ALS organizations such as ALS Finding a Cure, ALS Association and ALS ONE. The Phase 1 trial was funded by ALS Association by over $1 million.

CEO and Founder of Anelixis, Steven Perrin, Ph.D., stated that allograft rejection, autoimmune diseases and ALS represent large unmet medical needs and the company is looking forward to exploring AT-1501’s potential value as diligently and quickly as possible. Advancement of the drug into a strong clinical research program will be providing significant potential opportunities for all the patients both in the ALS and the diabetes communities, he added.

 

Source Credits- https://alsnewstoday.com/2019/11/21/anelixis-therapeutics-als-therapy-at-1501-phase-2-clinical-trial/



About Author

Saipriya Iyer

Email: [email protected]   

Saipriya Iyer

Saipriya Iyer develops content for Market Size Forecasters, Algosonline, and myriad other platforms. A computer engineer by profession, she ventured into the field of writing for the love of playing with words. Having had a previous experience of 3 years under her bel...

Read More

More News By Saipriya Iyer

Sanofi to acquire biotechnology firm Synthorx for $2.5 billion
Sanofi to acquire biotechnology firm Synthorx for $2.5 billion
By Saipriya Iyer

Sanofi, a renowned France based multinational pharmaceutical company, reportedly announced that it would be acquiring California based biotechnology firm, Synthorx, for $2.5 billion. Sanofi offered to purchase all outs...

uniQure updates follow up-data from hemophilia B therapy trials
uniQure updates follow up-data from hemophilia B therapy trials
By Saipriya Iyer

uniQure N.V, a renowned gene therapy firm that advances evolving therapies for all the patients who have severe medical needs, has recently confirmed that it has updated clinical data on three patients who were treated...

Veracyte inks deal with NanoString for nCounter® diagnostic platform
Veracyte inks deal with NanoString for nCounter® diagnostic platform
By Saipriya Iyer

San-Francisco based leading diagnostics company Veracyte has recently announced a definitive agreement with NanoString to acquire global license for the diagnostic use of nCounter® platform. Sources aware of the de...